INATAC: Innovative Antibody Therapies Against COVID-19
The UU-EMC-Harbour consortium will leverage their experience and expertise in coronaviruses, heavy-chain antibody platform technologies and establishment of relevant animal models. Using established technology platforms, they will isolate and characterise potent neutralising SBDs (in the form of nanobodies and human HCAbs) targeting the spike glycoprotein of SARS-CoV-2.
The goal is to develop ultra-potent binding domains (SBDs) and antibodies to neutralise the new coronavirus (SARS-CoV-2), which causes the respiratory disease COVID-19.
More detailed information
The UU-EMC Harbour
Role Erasmus MC: